Prenatal diagnosis of a dural sinus thrombosis with favorable outcome

2007 ◽  
Vol 27 (11) ◽  
pp. 1056-1058 ◽  
Author(s):  
J. Van Keirsbilck ◽  
G. Naulaers ◽  
M. Cannie ◽  
L. Lewi ◽  
P. Demaerel ◽  
...  
2009 ◽  
Vol 29 (8) ◽  
pp. 808-813 ◽  
Author(s):  
G. Legendre ◽  
O. Picone ◽  
J. M. Levaillant ◽  
J. Delavaucoupet ◽  
A. Ozanne ◽  
...  

2014 ◽  
Vol 14 (1) ◽  
pp. 16-22 ◽  
Author(s):  
Shaun P. Appaduray ◽  
James A. J. King ◽  
Alison Wray ◽  
Patrick Lo ◽  
Wirginia Maixner

Pediatric dural arteriovenous malformations (dAVMs) are rare lesions that have a high mortality rate and require complex management. The authors report 3 cases of pediatric dAVMs that presented with macrocrania and extracranial venous distension. Dural sinus thrombosis developed in 2 of the cases prior to any intervention, which is an unusual occurrence for this particular disease. All 3 cases were treated using staged endovascular embolization with a favorable outcome in 1 case and a poor outcome in the other 2 cases. Complications developed in all cases and included dural sinus thrombosis, parenchymal hemorrhage, intracranial venous hypertension, and seizures. The strategies and challenges used in managing these patients will be presented and discussed, along with a review of the literature. While outcomes remain poor, the authors conclude that prompt treatment with endovascular embolization provides the best results for children with these lesions. A well-established venous collateral circulation draining directly to the internal jugular veins may further improve the rate of favorable outcome after embolization.


2021 ◽  
Vol 58 (S1) ◽  
pp. 207-207
Author(s):  
A. Mora‐Garcia ◽  
E. Cisneros‐Bedoy ◽  
R.J. Martinez‐Portilla

Neurosurgery ◽  
2003 ◽  
Vol 52 (3) ◽  
pp. 534-544 ◽  
Author(s):  
Scott W. Soleau ◽  
Richard Schmidt ◽  
Steve Stevens ◽  
Anne Osborn ◽  
Joel D. MacDonald

Abstract OBJECTIVE Dural sinus thrombosis (DST) is an uncommon cause of stroke. The safest and most effective therapy for DST has not been conclusively identified. METHODS A retrospective chart review of data for 31 patients who were treated for DST at our institution between 1992 and 2001 was performed. Four treatment strategies were identified, i.e., 1) medical observation only, 2) systemic anticoagulation (AC) therapy with heparin, 3) endovascular chemical thrombolysis with urokinase or tissue plasminogen activator and concurrent systemic AC therapy, and 4) mechanical endovascular clot thrombolysis with concurrent systemic AC therapy. Complications and clinical outcomes were assessed for each group. RESULTS Patients treated solely with medical observation fared the worst; four of five patients experienced intracranial hemorrhagic complications, and only two of five exhibited clinical improvement. Patients who received systemic AC therapy experienced no hemorrhagic complications, even when pretreatment hemorrhage was present; 75% (six of eight patients) exhibited improvement with AC therapy alone. Chemical thrombolysis was very effective in restoring sinus patency (90% of patients); however, 30% of patients (3 of 10 patients) experienced hemorrhagic complications. Sixty percent of patients (6 of 10 patients) who underwent chemical thrombolysis exhibited clinical improvement. Patients who underwent mechanical thrombectomies demonstrated a low hemorrhagic complication rate, and most (88%) made good recoveries. CONCLUSION Therapy directed at the underlying clot in DST must begin without delay. Our results suggest that supportive medical management of DST, without therapy directed at the clot or clotting process, is not effective. Systemic AC therapy, even in the presence of intracerebral hemorrhage, seems to be safe. Heparin can be safely titrated to yield partial thromboplastin times of 60 to 70 seconds. Chemical clot thrombolysis is efficacious in opening occluded sinuses but may cause intracranial hemorrhage. We currently recommend either systemic AC therapy or systemic AC therapy in conjunction with mechanical clot thrombectomy as a safe effective treatment for DST.


Seizure ◽  
2014 ◽  
Vol 23 (2) ◽  
pp. 135-139 ◽  
Author(s):  
Vahid Davoudi ◽  
Kiandokht keyhanian ◽  
Mohammad Saadatnia

1993 ◽  
Vol 29 (1) ◽  
pp. 51
Author(s):  
Si Kyung Lee ◽  
Chun Hwan Han ◽  
Moon Ok Lee ◽  
Kyung Joo Park ◽  
Joo Hyuk Lee

1937 ◽  
Vol 11 (6) ◽  
pp. 755-771 ◽  
Author(s):  
Orville T. Bailey ◽  
George M. Hass

2003 ◽  
Vol 127 (10) ◽  
pp. 1359-1361 ◽  
Author(s):  
Christina L. Stephan ◽  
Karen SantaCruz ◽  
Corrie May ◽  
Steve B. Wilkinson ◽  
Mark T. Cunningham

Abstract Inherited thrombophilia is a risk factor for dural sinus thrombosis (DST). To our knowledge, this is the first description with autopsy findings of a patient with DST associated with heterozygous factor V Leiden and a short activated partial thromboplastin time (aPTT). A 51-year-old woman presented with a 3-day history of headache, nausea, right-sided weakness, and focal motor seizure; she died 3 days after admission. At autopsy, a gross examination showed hemorrhage of bilateral parietal lobes and left primary motor cortex, uncal and tonsillar herniation, and pulmonary embolus of the right upper lobe. A microscopic examination of the brain showed an organizing thrombus in the superior sagittal sinus, diffuse cerebral edema, and extensive venous congestion. Laboratory studies showed heterozygous factor V Leiden by polymerase chain reaction and a very short aPTT of 17 seconds (reference range, 22–30 seconds). The combination of a heterozygous factor V Leiden mutation and a short aPTT may have contributed to the fatal DST in this patient.


Sign in / Sign up

Export Citation Format

Share Document